Axonics, Inc., headquartered in Irvine, California, was founded in 2012 with a mission to improve the quality of life for individuals dealing with bladder and bowel dysfunction, affecting tens of millions globally. The company's flagship products include the Axonics Sacral Neuromodulation System, targeting overactive bladder and fecal incontinence, and the Bulkamid® hydrogel, addressing stress urinary incontinence in women.
Recent investment activity has been notable, with a significant $111.74 million Post-IPO Equity investment secured on 02 August 2022. This infusion of capital underscores investor confidence in Axonics' innovative solutions and market potential.
For more information on Axonics' groundbreaking work, interested parties can visit www.axonics.com and www.bulkamid.com.